(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 13.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.88%.
Opus Genetics's revenue in 2025 is $15,421,000.On average, 6 Wall Street analysts forecast IRD's revenue for 2025 to be $872,800,453, with the lowest IRD revenue forecast at $780,841,589, and the highest IRD revenue forecast at $960,685,570. On average, 6 Wall Street analysts forecast IRD's revenue for 2026 to be $1,480,268,131, with the lowest IRD revenue forecast at $851,293,462, and the highest IRD revenue forecast at $1,887,103,733.
In 2027, IRD is forecast to generate $1,188,455,995 in revenue, with the lowest revenue forecast at $322,904,416 and the highest revenue forecast at $2,698,977,694.